Vir Biotechnology, Inc. (VIR)
Chart Events
Performance Outlook
| Previous Close | 22.34 |
| Open | 22.57 |
| Bid | 22.87 x 900 |
| Ask | 22.87 x 1000 |
| Day's Range | 22.55 - 22.93 |
| 52 Week Range | 18.05 - 31.78 |
| Volume | |
| Avg. Volume | 1,026,911 |
| Market Cap | 3.032B |
| Beta (5Y Monthly) | 0.26 |
| PE Ratio (TTM) | 6.29 |
| EPS (TTM) | 3.61 |
| Earnings Date | May 03, 2023 - May 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 50.14 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VIR
Related Research
- Vir Biotechnology, Inc.VIR: What does Argus have to say about VIR?VIR BIOTECHNOLOGY INC has an Investment Rating of HOLD; a target price of $24.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.RatingFair ValueEconomic Moat8 days agoArgus Research
- Simply Wall St.
Strong week for Vir Biotechnology (NASDAQ:VIR) shareholders doesn't alleviate pain of three-year loss
For many investors, the main point of stock picking is to generate higher returns than the overall market. But in any...
- GlobeNewswire
Vir Biotechnology to Participate in the Barclays Global Healthcare Conference
SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 15, at 7:15 a.m. PT / 10:15 a.m. ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived the
- TheStreet.com
As Covid Threat Weakens, This Biotech Is Still Worth a Shot
Vir Biotechnology, Inc. is a biotech company facing the apparent winding down of the Covid crisis while sitting on a huge amount of net cash -- and with other projects in the pipeline. Vir uses this information to develop way of treating infectious diseases. This small biotech has one approved Covid-19 therapy in collaboration with GlaxoSmithKline (with significantly declining revenue) called sotrovimab and four others in the clinic.
